First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

The regimen of nivolumab plus ipilimumab (NI) has been recommended by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Malignant Pleural Mesothelioma (Version 1.2022) and Chin...

Source: Orphanet Journal of Rare Diseases - October 16, 2023 Category: Internal Medicine Authors: Liu Yang, Xiaobing Song, Wanxian Zeng, Zhiwei Zheng and Wenqiang Lin Tags: Research Source Type: research